BZAM (HAM:Z6A) Debt-to-Equity : 0.60 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BZAM Debt-to-Equity?

BZAM's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €26.80 Mil. BZAM's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €7.94 Mil. BZAM's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €57.67 Mil. BZAM's debt to equity for the quarter that ended in Sep. 2023 was 0.60.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BZAM's Debt-to-Equity or its related term are showing as below:

HAM:Z6A' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.25 Max: 0.6
Current: 0.6

During the past 7 years, the highest Debt-to-Equity Ratio of BZAM was 0.60. The lowest was 0.00. And the median was 0.25.

HAM:Z6A's Debt-to-Equity is ranked worse than
70.89% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HAM:Z6A: 0.60

BZAM Debt-to-Equity Historical Data

The historical data trend for BZAM's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BZAM Debt-to-Equity Chart

BZAM Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.08

0.33

0.24

0.26

BZAM Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.37	0.26	0.31	0.52	0.60

Competitive Comparison of BZAM's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, BZAM's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BZAM's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BZAM's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BZAM's Debt-to-Equity falls into.

BZAM Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BZAM's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.767	+	26.283)	/	119.221
	=	0.26

BZAM's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(26.8	+	7.939)	/	57.671
	=	0.60

BZAM (HAM:Z6A) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BZAM Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BZAM's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BZAM (HAM:Z6A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BZAM Ltd (HAM:Z6A) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BZAMF:USA Z6A:Germany BZAM:Canada

Address

200 Burrard Street, Suite 402, Vancouver, BC, CAN, V6C 3L6

Website

https://www.bzam.com

BZAM Ltd is a multi-licensed Canadian cannabis producer focused on branded consumer goods, cultivation, processing and people. The BZAM Cannabis family includes core brands BZAM, ness and TABLE TOP, and partner brands FRESH, Dunn Cannabis, SuperFlower and Snackbar. It operates facilities in the Lower Mainland, West Kootenay and Vancouver Island in British Columbia, and sister companies operate facilities in Edmonton, Alberta, as well as retail stores in Winnipeg, Manitoba and Emerald Park, Saskatchewan. The Company's business activities are conducted through two reportable operating segments which both consist of the production and distribution of cannabis and related products: BZAM and TGOD.

BZAM (HAM:Z6A) Headlines

No Headlines